| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We found that the misfolded protein/HLA class II complex is transported to the cell surface and autoantibodies against the complex are produced in various connective tissue diseases. We have discovered that Ro52 forms a complex with IgG/HLA class II and is transported to the cell surface. This anti-Ro52/IgG/HLA-class II complex antibody was positive in about 90% of patients with anti-MDA5 antibody-positive dermatomyositis which are prone to skin ulceration, and anti-synthetase antibody syndrome sera. Changes in antibody titers of the complex antibodies were associated with changes in disease status, suggesting that this complex may have pathogenic roles.
|
